Team II
Research profile
Recently, our research has been focused on the effects of new psychoactive substances (NPS), commonly referred to as designer drugs, on the central nervous system and their potential neurotoxic properties. These compounds have been detected, for example, in ecstasy pills, which are used as psychostimulats mainly by young people (16-24 years old, according to the GIS [Chief Sanitary Inspectorate] data). However, in addition to psychostimulatory properties, NPS produce also a wide range of adverse reactions. It is speculated that NPS may have neurotoxic properties, that are more severe than neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA) or methamphetamine. So far, we have found that single and multiple doses of NPS produce significant changes in the release of dopamine, serotonin, glutamate and γ-aminobutyric acid (GABA) in various structures of the rat brain. The above mentioned studies have been performed using microdialysis procedure in freely-moving animals and HPLC. We also measure monoamine levels in the brain to identify the deficits which are indicative of damaged nerve endings. DNA damage, determined using a comet assay, provides another progression marker of the neurodegenerative process. As a part of NPS research, our team uses also various behavioral tests. Separate ongoing research project conducted in our laboratory refers to neurotoxic effects of MDMA administered jointly with caffeine, the substance found in "party pills" used for recreational purposes. Following single and repeated administration, both substances caused drastic changes in monoamine release in mouse brain. Significant DNA damage was also observed, indicating the presence of oxidative stress. We are also involved in the collaboration with other departments in the Institute of Pharmacology. These studies include, among others, evaluation of combined antidepressant and antipsychotic treatments as a novel alternative therapy in drug-resistant depression and chronic schizophrenia. For this purpose, the release of dopamine and serotonin in the rat frontal cortex is examined. Our team also participates in the search for new antidepressants and antipsychotics within a large group of newly synthesized ligands and modulators of metabotropic glutamate receptor subtypes. Analysis of neurotransmitters is carried out using high-performance liquid chromatography (HPLC) with electrochemical, coulochemic and fluorescence detection.
Research methods:
- Brain microdialysis in rats and mice
- High performance liquid chromatography (HPLC) with electrochemical, coulochemical and fluorescence detection
- Assessment of DNA damage using a comet assay
- Behavioral tests
The most important two discoveries in the last 3 years
- Demonstration of antioxidant and anti-inflammatory properties of A2A receptor antagonists as a new, non-dopaminergic treatment in Parkinson's disease.
- Caffeine-induced augmentation of psychostimulant and neurotoxic effects of MDMA (ecstasy) in mice.
Keywords:
- dopamine, serotonin, glutamate, GABA, adenosine
- receptors and the release of neurotransmitters in vivo (microdialysis)
- new psychoactive substances (NPS)
- neurodegeneration
- neurotoxicity
- oxidative DNA damage (comet test)
- oxidative stress, free radicals
- metabotropic receptor ligands for glutamate
- antidepressants and atypical antipsychotics
-
Neurochemical and Behavioral Effects of a New Hallucinogenic Compound 25B-NBOMe in Rats.
Adam Wojtas, Monika Herian, Mateusz Skawski, Małgorzata Sobocińska, Alejandro González-Marín, Karolina Noworyta-Sokołowska, Krystyna Gołembiowska
Neurotoxicity research, 10.1007/s12640-020-00297-8
PMID:33337517 -
Contribution of serotonin receptor subtypes to hallucinogenic activity of 25I-NBOMe and to its effect on neurotransmission.
Monika Herian, Adam Wojtas, Małgorzata Katarzyna Sobocińska, Mateusz Skawski, Alejandro González-Marín, Krystyna Gołembiowska
Pharmacological reports : PR, 10.1007/s43440-020-00181-4
PMID:33174181 -
Hallucinogen-Like Action of the Novel Designer Drug 25I-NBOMe and Its Effect on Cortical Neurotransmitters in Rats.
Monika Herian, Adam Wojtas, Katarzyna Kamińska, Paweł Świt, Anna Wach, Krystyna Gołembiowska
Neurotoxicity research, 10.1007/s12640-019-00033-x
PMID:30989482 -
Risperidone and escitalopram co-administration: A potential treatment of schizophrenia symptoms with less side effects.
Katarzyna Kamińska, Karolina Noworyta-Sokołowska, Alexandra Jurczak, Anna Górska, Zofia Rogóż, Krystyna Gołembiowska
Pharmacological reports : PR, S1734-1140(16)30166-9 10.1016/j.pharep.2016.09.010
PMID:27755991 -
Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats.
Karolina Noworyta-Sokołowska, Katarzyna Kamińska, Grzegorz Kreiner, Zofia Rogóż, Krystyna Gołembiowska
Neurotoxicity research,
PMID:27461536 -
Neurochemical and behavioral studies on the 5-HT1A-dependent antipsychotic action of the mGlu4 receptor agonist LSP4-2022.
Monika Woźniak, Krystyna Gołembiowska, Karolina Noworyta-Sokołowska, Francine Acher, Paulina Cieślik, Magdalena Kusek, Krzysztof Tokarski, Andrzej Pilc, Joanna M Wierońska
Neuropharmacology, S0028-3908(16)30278-7 10.1016/j.neuropharm.2016.06.025
PMID:27465045 -
The influence of aripiprazole and olanzapine on neurotransmitters level in frontal cortex of prenatally stressed rats.
P Ratajczak, K Kus, K Gołembiowska, K Noworyta-Sokołowska, A Woźniak, T Zaprutko, E Nowakowska
Environmental toxicology and pharmacology, S1382-6689(16)30185-5 10.1016/j.etap.2016.07.007
PMID:27458700 -
NMDA Receptors on Dopaminoceptive Neurons Are Essential for Drug-Induced Conditioned Place Preference.
Magdalena Sikora, Krzysztof Tokarski, Bartosz Bobula, Joanna Zajdel, Kamila Jastrzębska, Przemysław Eligiusz Cieślak, Magdalena Zygmunt, Joanna Sowa, Magdalena Smutek, Katarzyna Kamińska, Krystyna Gołembiowska, David Engblom, Grzegorz Hess, Ryszard Przewlocki, Jan Rodriguez Parkitna
eNeuro, 10.1523/ENEURO.0084-15.2016 ENEURO.0084-15.2016
PMID:27294197 -
Melatonin Supports CYP2D-Mediated Serotonin Synthesis in the Brain.
Anna Haduch, Ewa Bromek, Jacek Wójcikowski, Krystyna Gołembiowska, Władysława A Daniel
Drug metabolism and disposition: the biological fate of chemicals, 10.1124/dmd.115.067413
PMID:26884482 -
Alterations of Bio-elements, Oxidative, and Inflammatory Status in the Zinc Deficiency Model in Rats.
Urszula Doboszewska, Bernadeta Szewczyk, Magdalena Sowa-Kućma, Karolina Noworyta-Sokołowska, Paulina Misztak, Joanna Gołębiowska, Katarzyna Młyniec, Beata Ostachowicz, Mirosław Krośniak, Agnieszka Wojtanowska-Krośniak, Krystyna Gołembiowska, Marek Lankosz, Wojciech Piekoszewski, Gabriel Nowak
Neurotoxicity research, 10.1007/s12640-015-9571-7
PMID:26581375 -
Effect of Some Psychoactive Drugs Used as 'Legal Highs' on Brain Neurotransmitters.
Krystyna Gołembiowska, Alexandra Jurczak, Katarzyna Kamińska, Karolina Noworyta-Sokołowska, Anna Górska
Neurotoxicity research, 10.1007/s12640-015-9569-1
PMID:26501352 -
5-HT7 receptor modulates GABAergic transmission in the rat dorsal raphe nucleus and controls cortical release of serotonin.
Magdalena Kusek, Joanna Sowa, Katarzyna Kamińska, Krystyna Gołembiowska, Krzysztof Tokarski, Grzegorz Hess
Frontiers in cellular neuroscience, 10.3389/fncel.2015.00324
PMID:26347612 -
Anti-inflammatory, antioxidant, and antiparkinsonian effects of adenosine A2A receptor antagonists.
Małgorzata Zygmunt, Krystyna Gołembiowska, Anna Drabczyńska, Katarzyna Kieć-Kononowicz, Jacek Sapa
Pharmacology, biochemistry, and behavior, S0091-3057(15)00061-1 10.1016/j.pbb.2015.02.020
PMID:25735490 -
The cytochrome P450 2D-mediated formation of serotonin from 5-methoxytryptamine in the brain in vivo: a microdialysis study.
Anna Haduch, Ewa Bromek, Marta Kot, Katarzyna Kamińska, Krystyna Gołembiowska, Wladyslawa A Daniel
Journal of neurochemistry, 10.1111/jnc.13031
PMID:25581337 -
The role of adenosine A1 and A2A receptors in the caffeine effect on MDMA-induced DA and 5-HT release in the mouse striatum.
A M Górska, K Gołembiowska
Neurotoxicity research, 10.1007/s12640-014-9501-0
PMID:25391902
-
Pharmacological properties and neurotoxicity of novel NBOMe derivatives, Professor Krystyna Gołembiowska, PhD
OPUS11 2016/21/B/NZ7/01131
-
, Professor Krystyna Gołembiowska, PhD
-
, Professor Krystyna Gołembiowska, PhD
-
, Professor Krystyna Gołembiowska, PhD
-
, Professor Krystyna Gołembiowska, PhD
-
, Professor Krystyna Gołembiowska, PhD
-
, Professor Krystyna Gołembiowska, PhD
-
, Professor Krystyna Gołembiowska, PhD
-
, Professor Krystyna Gołembiowska, PhD
-
, Professor Krystyna Gołembiowska, PhD
-
, Professor Krystyna Gołembiowska, PhD
-
, Professor Krystyna Gołembiowska, PhD
-
, Professor Krystyna Gołembiowska, PhD
-
, Professor Krystyna Gołembiowska, PhD
-
, Professor Krystyna Gołembiowska, PhD
Professor Krystyna Gołembiowska, PhD
Phone number: +48 12 6623211E-mail: nfgolemb@cyf-kr.edu.pl
interests
techniques
keywords
- adenosine
- adenosine receptors
- amphetamine
- animal models
- antidepressants
- antipsychotics
- apoptosis
- behavioural analysis
- chronic schizophrenia
- cognitive functions
- depression
- dopamine
- escitalopram
- excitotoxicity
- frontal cortex
- GABA
- glutamate
- glutamatergic receptors
- MDMA
- memory
- metabotropic glutamate receptors
- mirtazapine
- monoamines
- neurodegeneration
- neurotoxicity
- nigro-striatal dopaminergic system
- noradrenaline
- Parkinson's disease
- psychosis
- rat
- risperidone
- schizophrenia
- serotonin
- serotonin receptors
- striatum
- treatment-resistant depression
- working memory